JP2022537555A - ウイルスベースの遺伝子療法による治療方法 - Google Patents

ウイルスベースの遺伝子療法による治療方法 Download PDF

Info

Publication number
JP2022537555A
JP2022537555A JP2021575397A JP2021575397A JP2022537555A JP 2022537555 A JP2022537555 A JP 2022537555A JP 2021575397 A JP2021575397 A JP 2021575397A JP 2021575397 A JP2021575397 A JP 2021575397A JP 2022537555 A JP2022537555 A JP 2022537555A
Authority
JP
Japan
Prior art keywords
patient
gene therapy
viral
smrt
ncor2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021575397A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022537555A5 (https=
Inventor
イヴァン ビリク
バージット ライペルト
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of JP2022537555A publication Critical patent/JP2022537555A/ja
Publication of JP2022537555A5 publication Critical patent/JP2022537555A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2021575397A 2019-06-20 2020-06-19 ウイルスベースの遺伝子療法による治療方法 Pending JP2022537555A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962864404P 2019-06-20 2019-06-20
US62/864,404 2019-06-20
US201962867172P 2019-06-26 2019-06-26
US62/867,172 2019-06-26
PCT/US2020/038643 WO2020257586A2 (en) 2019-06-20 2020-06-19 Method of treatment with viral-based gene therapy

Publications (2)

Publication Number Publication Date
JP2022537555A true JP2022537555A (ja) 2022-08-26
JP2022537555A5 JP2022537555A5 (https=) 2023-06-23

Family

ID=71579659

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021575397A Pending JP2022537555A (ja) 2019-06-20 2020-06-19 ウイルスベースの遺伝子療法による治療方法

Country Status (5)

Country Link
US (1) US20200405883A1 (https=)
EP (1) EP3986481A2 (https=)
JP (1) JP2022537555A (https=)
CN (1) CN114375205A (https=)
WO (1) WO2020257586A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114277057B (zh) * 2021-07-09 2023-10-13 上海天泽云泰生物医药有限公司 用于治疗或预防b型血友病的重组腺相关病毒载体和方法
CN115772214B (zh) * 2022-11-30 2023-09-29 湖南家辉生物技术有限公司 F8突变体蛋白、f8基因突变体、检测f8基因突变体的引物组合、试剂及应用
TW202444398A (zh) * 2023-01-09 2024-11-16 美商拜奧馬林製藥公司 表觀遺傳修飾劑改善aav基因療法之耐久性

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017531652A (ja) * 2014-10-06 2017-10-26 アルスロジェン ビー．ブイ．Ａｒｔｈｒｏｇｅｎ Ｂ．Ｖ． Ａａｖに基づく遺伝子治療

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795965A (en) 1991-04-25 1998-08-18 Chugai Seiyaku Kabushiki Kaisha Reshaped human to human interleukin-6 receptor
US5831005A (en) 1992-09-24 1998-11-03 Chiron Corporation Synthesis of N-substituted oligomers
US5877278A (en) 1992-09-24 1999-03-02 Chiron Corporation Synthesis of N-substituted oligomers
US6458563B1 (en) 1996-06-26 2002-10-01 Emory University Modified factor VIII
US6531298B2 (en) 1997-07-21 2003-03-11 The University Of North Carolina At Chapel Hill Factor IX antihemophilic factor with increased clotting activity
US20020014242A1 (en) * 2000-07-31 2002-02-07 Abraham Scaria Use of rapamycin to inhibit immune response and induce tolerance to gene therapy vector and encoded transgene products
PT2308888T (pt) 2001-11-14 2017-05-03 Janssen Biotech Inc Anticorpos anti-il-6, composições, métodos e utilizações
JO3058B1 (ar) 2005-04-29 2017-03-15 Applied Molecular Evolution Inc الاجسام المضادة لمضادات -اي ال-6,تركيباتها طرقها واستعمالاتها
ATE550353T1 (de) 2005-12-30 2012-04-15 Merck Patent Gmbh Die bindung von mit il-6ralpha komplexiertem il-6 an gp130 verhindernde anti-il-6-antikörper
JP5307708B2 (ja) 2006-06-02 2013-10-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトｉｌ−６受容体に対する高親和性抗体
CN101563365B (zh) 2006-08-03 2012-10-31 瓦西尼斯公司 抗-il-6单克隆抗体及其用途
WO2008069942A2 (en) 2006-12-05 2008-06-12 Biogen Idec Ma Inc. Novel methods of enhancing delivery of a gene therapy vector using steroids
MX2010012031A (es) 2008-05-13 2011-01-20 Novimmune Sa Anticuerpos anti-il-6/il-6r y metodos de uso de los mismos.
MX2011000071A (es) 2008-07-02 2011-05-03 Emergent Product Dev Seattle Inmunoterapeuticos de interleucina-6 (il6).
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
AU2009313958B2 (en) 2008-11-13 2015-09-10 Femta Pharmaceuticals, Inc. Humanized anti-IL-6 antibodies
WO2010115995A2 (en) 2009-04-10 2010-10-14 Ablynx Nv Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
WO2011031657A1 (en) 2009-09-08 2011-03-17 Centocor Ortho Biotech Inc. Use of an anti-il6 antibody to decrease hepcidin in cancer patients
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
EP2640745B1 (en) 2010-09-10 2018-11-07 MedImmune Limited Bivalent and bispecific anti-il6/anti-il23 antibodies
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
EP3283126B1 (en) * 2015-04-16 2019-11-06 Emory University Recombinant promoters and vectors for protein expression in liver and use thereof
CA2991637C (en) * 2015-07-31 2022-07-05 Medimmune Limited Methods for treating hepcidin-mediated disorders
TW202446416A (zh) * 2015-09-24 2024-12-01 美商拜奧馬林製藥公司 腺相關病毒因子viii載體、相關病毒粒子及包含其之治療調配物
WO2017079443A1 (en) 2015-11-03 2017-05-11 Sanofi Biotechnology Compositions comprising il6r antibodies for the treatment of uveitis and macular edema and methods of using same
EA202190827A1 (ru) * 2015-11-13 2021-11-30 Баксалта Инкорпорейтед Вирусные векторы, кодирующие рекомбинантные варианты fviii с повышенной экспрессией для генной терапии гемофилии a
CA3005565A1 (en) * 2015-11-13 2017-05-18 Baxalta Incorporated Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a
WO2018029182A1 (en) 2016-08-08 2018-02-15 Ablynx N.V. Il-6r single variable domain antibodies for treatment of il-6r related diseases
WO2018112237A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with an il-6r inhibitor
MX2019008143A (es) * 2017-01-07 2020-01-13 Selecta Biosciences Inc Dosificación sistemática de inmunosupresores acoplados a nanoportadores sintéticos.
KR20200012823A (ko) * 2017-02-01 2020-02-05 예일 유니버시티 이뇨제 내성의 치료
US11617797B2 (en) * 2017-04-28 2023-04-04 David T. Tran Multi-targeted multi-valent ligand drug particles for the treatment and prevention of diseases and conditions
CN110945127B (zh) 2017-05-22 2024-07-12 武田药品工业株式会社 用于血友病b的基因疗法的编码具有增加的表达的重组fix的病毒载体
CN111051343B (zh) 2017-09-13 2022-11-22 江苏恒瑞医药股份有限公司 Il-6r抗体、其抗原结合片段及医药用途
CN109867723B (zh) 2017-12-05 2022-06-17 南京金斯瑞生物科技有限公司 抗人il6单克隆抗体及其制备方法和用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017531652A (ja) * 2014-10-06 2017-10-26 アルスロジェン ビー．ブイ．Ａｒｔｈｒｏｇｅｎ Ｂ．Ｖ． Ａａｖに基づく遺伝子治療

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KLAUDIA KURANDA ET AL.: ""Exposure to wild-type AAV drives distinct capsid immunity profiles in humans"", JOURNAL OF CLINICAL INVESTIGATION, vol. 128, no. 12, JPN6024027726, 22 October 2018 (2018-10-22), pages 5267 - 5279, ISSN: 0005613709 *
VICTORIA M. VELAZQUEZ ET AL.: ""Effective Depletion of Pre-existing Anti-AAV Antibodies Requires Broad Immune Targeting"", MOLECULAR THERAPY - METHODS & CLINICAL DEVELOPMENT, vol. 4, JPN6024027727, March 2017 (2017-03-01), pages 159 - 168, ISSN: 0005613710 *

Also Published As

Publication number Publication date
EP3986481A2 (en) 2022-04-27
CN114375205A (zh) 2022-04-19
WO2020257586A3 (en) 2021-03-04
US20200405883A1 (en) 2020-12-31
WO2020257586A2 (en) 2020-12-24

Similar Documents

Publication Publication Date Title
Herzog et al. Influence of vector dose on factor IX-specific T and B cell responses in muscle-directed gene therapy
JP6462044B2 (ja) 第ｖｉｉｉ因子療法を受けている個体における第ｖｉｉｉ因子に対する免疫原性を低下させる方法
KR102766526B1 (ko) 간-특이적 작제물인, 인자 viii 발현 카세트 및 이의 사용 방법
Vercelli et al. Regulation of IgE synthesis in humans: a tale of two signals
JP6831779B2 (ja) 修飾された第ｉｘ因子、並びに、細胞、器官及び組織への遺伝子導入のための組成物、方法及び使用
JP6290270B2 (ja) 遺伝子操作した樹状細胞および癌の治療のための使用
Wang et al. Major role of local immune responses in antibody formation to factor IX in AAV gene transfer
AU2017214378A1 (en) Optimized Factor VIII genes
JP2022537555A (ja) ウイルスベースの遺伝子療法による治療方法
US20240117364A1 (en) Synthetic immunomodulation with a crispr super-repressor in vivo
US20230133243A1 (en) Conditioning regimens for in vivo gene therapy
US20230159649A1 (en) Methods and combinations for dual targeting of tnf family members
TW201723180A (zh) 用於ａ型血友病基因治療之編碼表現增加之重組ｆｖｉｉｉ變異體之病毒載體
Nayak et al. Prevention and reversal of antibody responses against factor IX in gene therapy for hemophilia B
CN119095612A (zh) 用于在长期停止gaa酶替代疗法的情况下治疗庞贝病的治疗性腺相关病毒
TW202006141A (zh) 使用編碼具有增加表現的重組fviii變異體之病毒載體的a型血友病之基因療法
US8063022B1 (en) Methods for preventing formation of inhibitory antibodies in the setting of gene therapy
US20240269241A1 (en) Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression
US20250276092A1 (en) Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response
US20250242056A1 (en) Methods and compositions for using plasma cell depleting agents and/or b cell depleting agents to suppress host anti-aav antibody response and enable aav transduction and re-dosing
RU2799048C2 (ru) Улучшение клинических параметров посредством экспрессии фактора viii
WO2024238591A2 (en) Methods of treating anti-aav seropositive hemophilia patients
JP2003146909A (ja) 治療用ポリペプチドに対する免疫寛容の誘導
HK40121378A (zh) 用於在长期停止gaa酶替代疗法的情况下治疗庞贝病的治疗性腺相关病毒
JP2023506171A (ja) 発現が上昇した組換えｆｖｉｉｉバリアントをコードするウイルスベクターを使用する、血友病ａの遺伝子療法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230615

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230615

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230818

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240716

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240912

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241114

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250120

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250319

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250610